PCVX vs. UTHR: Vaxcyte vs. United Therapeutics Stock Comparison

November 11, 2026

How do Vaxcyte (PCVX) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Vaxcyte (PCVX) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

United Therapeutics (UTHR) has more than two decades of public-market history since June 17, 1999, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Vaxcyte (PCVX) and United Therapeutics (UTHR)
Profile Item	PCVX	UTHR
Name	Vaxcyte Inc.	United Therapeutics Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	10.11 billion USD	23.94 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	June 12, 2020	June 17, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

PCVX

UTHR

GSPC

Vaxcyte (PCVX) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Vaxcyte (PCVX) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Vaxcyte (PCVX) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Vaxcyte (PCVX) and United Therapeutics (UTHR)
Metric	PCVX	UTHR
Total Return (1Y)	59.00%	28.77%
Total Return (3Y, Annualized)	11.29%	37.63%
Total Return (5Y, Annualized)	21.60%	23.78%

Risk Profile

Drawdown History

PCVX

UTHR

GSPC

Vaxcyte (PCVX) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Vaxcyte (PCVX) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Vaxcyte (PCVX) and United Therapeutics (UTHR)
Metric	PCVX	UTHR
Volatility (1Y, Annualized)	56.01%	35.00%
Beta (5Y)	1.26	0.49
Max Drawdown (5Y)	-76.22%	-33.00%
Avg. Volume (3M)	2.12M	694.55K

Risk-Adjusted Performance

Risk-Return Positioning

PCVX and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Vaxcyte (PCVX) and United Therapeutics (UTHR)
Metric	PCVX	UTHR
Sharpe Ratio (1Y)	0.98	0.70
Sortino Ratio (1Y)	1.76	1.29

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile United Therapeutics (UTHR) reports 19.13%, ranking against industry peers normally.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
PCVX: -42.68%
Q1: -64.05%
Min: -167.77%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

United Therapeutics (UTHR) at 38.61% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
PCVX: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

United Therapeutics (UTHR) at 28.99% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 83.12%
Q3: 14.77%
PCVX: 0.00%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Vaxcyte (PCVX) and United Therapeutics (UTHR)
Metric	PCVX	UTHR
ROE (TTM)	-42.68%	19.13%
ROA (TTM)	-24.98%	10.91%
Net Margin (TTM)	0.00%	38.61%
Operating Margin (TTM)	0.00%	28.99%
Gross Margin (TTM)	0.00%	86.34%

Growth

Revenue Growth

Only one side can be read here: United Therapeutics (UTHR) reports revenue growth of 10.61%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Vaxcyte (PCVX) and United Therapeutics (UTHR)
Metric	PCVX	UTHR
Revenue Growth (YoY)	--	10.61%
Revenue Growth (3Y CAGR)	--	18.02%
EPS Growth (YoY)	--	13.07%
EPS Growth (3Y CAGR)	--	22.92%

Financial Strength

Current Ratio (MRQ)

Both Vaxcyte (PCVX) at 4.56 and United Therapeutics (UTHR) at 4.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max: 25.13
Q3: 12.13
Median: 5.52
PCVX: 4.56
Q1: 2.47
Min: 0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Vaxcyte (PCVX) carries debt-to-equity ratio of 0.09 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max: 1.42
Q3: 0.65
Median: 0.15
PCVX: 0.09
Q1: 0.02
Min: 0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; PCVX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Vaxcyte (PCVX) and United Therapeutics (UTHR)
Metric	PCVX	UTHR
Current Ratio (MRQ)	4.56	4.61
Debt / Equity (MRQ)	0.09	--
Net Debt / EBITDA	--	-1.53

Dividends

Dividend Yield (TTM)

Neither Vaxcyte (PCVX) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Vaxcyte (PCVX) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Vaxcyte (PCVX) and United Therapeutics (UTHR)
Metric	PCVX	UTHR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
PCVX: --

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): PCVX does not report P/E ratio, so it has no value marker; UTHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for United Therapeutics (UTHR), whose P/S ratio of 7.51 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01
PCVX: --

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): PCVX does not report P/S ratio, so it has no value marker; UTHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

On P/B ratio, both Vaxcyte (PCVX) at 3.83 and United Therapeutics (UTHR) at 3.80 are valued close to their industries’ norm against book — neither stands out from peers.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max: 13.53
Q3: 6.54
PCVX: 3.83
Median: 3.25
Q1: 1.69
Min: -5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Vaxcyte (PCVX) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Vaxcyte (PCVX) and United Therapeutics (UTHR)
Metric	PCVX	UTHR
P/E Ratio (TTM)	--	21.22
P/S Ratio (TTM)	--	7.51
P/B Ratio (MRQ)	3.83	3.80
Free Cash Flow Yield (TTM)	-5.24%	1.90%